Cytel Transforms Biopharmaceutical Go/No-Go Decision-Making with OK GO Software

January 1, 2019

Stock_Okgo_Road_Long_Exposure_web-1Cytel announced the launch of OK GO, the first commercially available software to underpin quantitative go/no-go decision-making frameworks in clinical trials.  The innovative product helps sponsors make faster, more robust decisions about their products to improve their R&D productivity.  OK GO is the commercial release of custom software originally developed as a collaboration between AstraZeneca and Cytel scientists to enhance the established decision-making framework in AstraZeneca’s early clinical development group.

Read press release